Recbio

📍 Taizhou, China🗓 Founded 2012👥 21 employees💰 Last funded Nov 2020
Biotechnology🌐 recbio.cn
Website LinkedIn
Recbio(HKEX:02179) is an innovative vaccine company founded in 2012. With the vision of "Become the Leader of Innovative Vaccine in the Future," Recbio takes "Protect Human Health with Best-in-Class Vaccines" as its mission. It has established three major cutting-edge technology platforms including novel adjuvants platform, protein engineering platform, and immunological evaluation platform. Recbio has a high-value vaccine portfolio consisted of recombinant protein, HPV vaccine candidates, COVID-19 vaccine candidates, shingles vaccine candidates, influenza vaccine candidates, adults TB vaccine candidates, etc. The core scientific team has more than 20 years of experience in the development and commercialization of innovative vaccines. For more information, please visit https://www.recbio.cn/.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2012
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
China
1
Frequently asked questions
Who invested in Recbio?
Recbio has 1 investors on record on gritt.io and 1 late-stage investors.
When did Recbio last raise funding?
The most recent investment in Recbio recorded on gritt.io was in November 2020.
When was Recbio founded?
Recbio was founded in 2012.
What industry is Recbio in?
Recbio operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Recbio based?
Recbio is headquartered in Taizhou, China.